GlaxoSmithKline Pakistan (KAR:GLAXO) ROCE %: 46.81% (As of Mar. 2026)


KAR:GLAXO GlaxoSmithKline Pakistan Ltd KAR:GLAXO
92 GF Score
Price ₨370.25
GF Value ₨324.26
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GlaxoSmithKline Pakistan ROCE %?

GlaxoSmithKline Pakistan KAR:GLAXO +1.66% 92 ROCE % is 46.81% as of Mar. 2026. GuruFocus rates KAR:GLAXO with a GF Score™ of 92/100 and a GF Value™ of ₨324.26 (Modestly Overvalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. GlaxoSmithKline Pakistan's annualized ROCE % for the quarter that ended in Mar. 2026 was 46.81%.

GlaxoSmithKline Pakistan  (KAR:GLAXO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

GlaxoSmithKline Pakistan ROCE % Related Terms

GlaxoSmithKline Pakistan ROCE % Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline Pakistan's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pakistan ROCE % Chart

GlaxoSmithKline Pakistan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.43 22.84 9.16 39.10 50.94

GlaxoSmithKline Pakistan Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.46 45.07 40.43 74.74 46.81
KAR:GLAXO
92GF Score
GlaxoSmithKline Pakistan Ltd KAR:GLAXO
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlaxoSmithKline Pakistan ROCE % Calculation

GlaxoSmithKline Pakistan's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=16726.216/( ( (45055.459 - 14932.619) + (50683.502 - 15133.866) )/ 2 )
=16726.216/( (30122.84+35549.636)/ 2 )
=16726.216/32836.238
=50.94 %

GlaxoSmithKline Pakistan's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=17245.412/( ( (50683.502 - 15133.866) + (53990.416 - 15858.478) )/ 2 )
=17245.412/( ( 35549.636 + 38131.938 )/ 2 )
=17245.412/36840.787
=46.81 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 46.81% mean?
GlaxoSmithKline Pakistan (KAR:GLAXO) has a ROCE % of 46.81% as of Mar. 2026.
Is GlaxoSmithKline Pakistan's ROCE % too high?
GlaxoSmithKline Pakistan's current ROCE % is 46.81%. The Drug Manufacturers industry median ROCE % is 7.03. GlaxoSmithKline Pakistan's value of 46.81% is 565.9% above this industry median. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's ROCE % compare to ZTS and UTHR?
GlaxoSmithKline Pakistan's ROCE % of 46.81% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. GlaxoSmithKline Pakistan's value of 46.81% is 565.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pakistan's current ROCE % of 46.81% is 565.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pakistan's current ROCE % is 46.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨324.26, compared to a current price of ₨370.25 — trading 14.2% above its estimated fair value. The current ROCE % is 46.81% and 565.9% above the Drug Manufacturers industry median of 7.03. GlaxoSmithKline Pakistan's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current ROCE % is 46.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued. The current stock price of ₨370.25 is trading 14.2% above its estimated GF Value™ of ₨324.26. GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.

Key valuation signals for KAR:GLAXO:

  • ROCE %: 46.81%
  • GF Value™: ₨324.26 vs. price of ₨370.25 (14.2% above fair value)
  • GF Score™: 92/100 with 1 warning sign
  • Industry Position: 565.9% above the Drug Manufacturers median

No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GlaxoSmithKline Pakistan Business Description

Address 35, Dockyard Road, West Wharf, Karachi, PAK, 74000
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
92GF Score

Get the complete analysis for KAR:GLAXO

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨370.25
Price
₨324.26
GF Value